Sanofi poised for $4B bond issue

Sanofi-Aventis is set to sell $4 billion in Euro-denominated bonds, divided into two tranches of $2 billion each: one with four-year maturities and the other with seven-year maturities. So far this year, drugmakers have been successful with bond investors on both sides of the Atlantic, with Roche completing record issues in both U.S. and Euro markets. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.